2Y3A
Crystal structure of p110beta in complex with icSH2 of p85beta and the drug GDC-0941
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | ESRF BEAMLINE ID14-4 |
Synchrotron site | ESRF |
Beamline | ID14-4 |
Temperature [K] | 100 |
Detector technology | CCD |
Collection date | 2009-12-05 |
Detector | ADSC QUANTUM 315r |
Spacegroup name | P 65 2 2 |
Unit cell lengths | 134.314, 134.314, 428.062 |
Unit cell angles | 90.00, 90.00, 120.00 |
Refinement procedure
Resolution | 44.680 - 3.300 |
R-factor | 0.2372 |
Rwork | 0.234 |
R-free | 0.29600 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | 2whg |
RMSD bond length | 0.010 |
RMSD bond angle | 1.350 |
Data reduction software | MOSFLM |
Data scaling software | SCALA |
Phasing software | PHASER |
Refinement software | BUSTER (2.8.0) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 44.000 | 3.500 |
High resolution limit [Å] | 3.300 | 3.300 |
Rmerge | 0.100 | 0.670 |
Number of reflections | 34250 | |
<I/σ(I)> | 10.4 | 1.9 |
Completeness [%] | 98.9 | 99.9 |
Redundancy | 5.2 | 5.4 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | 6 | PROTEIN WAS CRYSTALLIZED FROM 12% PEG 3350, 0.1 M POTASSIUM CITRATE PH 6, 0.4 M LITHIUM SULFATE |